Global Pediatric Growth Hormones Market

Pediatric Growth Hormones Comprehensive Study by Route of Administration (Intravenous, Intramuscular, Subcutaneous, Oral), Indication (Growth Hormone Deficiency, Turner Syndrome, Renal Insufficiency, Short Stature, Prader-Willi Syndrome, Noonan Syndrome, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) Players and Region - Global Market Outlook to 2026

Pediatric Growth Hormones Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Pediatric Growth Hormones Market?

Adolescent The pituitary gland produces growth hormones, which are necessary for children's growth. Growth hormones play a crucial role in metabolic and physiological processes during one's life. Cell replication and regeneration are stimulated by growth hormones in both children and adults. Many companies are concentrating their efforts on developing new drugs to treat growth hormone deficiency. Over the projected era, clinical trial and product development activities are expected to fuel the growth of pediatric growth hormones.

The market study is being classified and major geographies with country level break-up.

Merck KGaA (Germany), Novo Nordisk A/S (Denmark), Ferring B.V (Netherlands), Genentech, Inc. (United States), Pfizer Inc. (United States), Eli Lilly & Company (United States), Novartis AG (Switzerland) and BioPartners GmbH (Switzerland) are some of the key players profiled in the study.

The top firms are in a competition that has their strong R&D backup for research studies and the further things which are required to get approval for such complicated drugs and enhance the treatment medications. There are firms mainly from the USA and playing a major role in the research area of Biopharmaceuticals. The mergers and acquisitions are other options to change the market strategies and earn more reputation in the market. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Pediatric Growth Hormones market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Pediatric Growth Hormones market by Type, Application and Region.

On the basis of geography, the market of Pediatric Growth Hormones has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing Number of Endocrine Disorders
  • Increasing Number of Cases of Pituitary Gland Tumors

Market Trend
  • Rising Clinical Trial and Product Development Activities

Restraints
  • High Cost of the Pediatric Growth Hormone Injections
  • Low Awareness among the General Population regarding Growth Hormone Deficiency

Opportunities
  • Increasing Pediatric Diagnostic Campaigns and Programs in Developing Countries
  • Growing Treatment Affordability Rate and Awareness Rate in Developed Countries

Challenges
  • Side Effects Associated with the Hormonal Therapy


In Oct 2020, Pfizer Inc. and OPKO Health Inc. announced that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in children 3 to <18 years of age with growth hormone deficiency (GHD), met its primary endpoint of improved treatment burden compared to GENOTROPIN® (somatropin) for injection administered once-daily., and In May 2019, Ascendis Pharma A/S announced preliminary results from the phase 3 fliGHt Trial of TransCon Growth Hormone (hGH). The results indicated treatment with TransCon hGH was safe and well-tolerated in subjects with pediatric growth hormone deficiency (GHD) who were previously treated with commercially available daily growth hormone therapies
In Jan 2021, Pfizer Inc. and OPKO Health Inc. announced that the US Food and Drug Administration (FDA) has accepted for filing the initial Biologics License Application (BLA) for somatrogon, a long-acting human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency (GHD).

Key Target Audience
Pediatric Growth Hormones Treatment Manufacturers, Research and Development (R&D) Companies, Hospitals and Clinics, Academic Institutes and Universities, Potential Investors and Others

Report Objectives / Segmentation Covered

By Route of Administration
  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Oral

By Indication
  • Growth Hormone Deficiency
  • Turner Syndrome
  • Renal Insufficiency
  • Short Stature
  • Prader-Willi Syndrome
  • Noonan Syndrome
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Number of Endocrine Disorders
      • 3.2.2. Increasing Number of Cases of Pituitary Gland Tumors
    • 3.3. Market Challenges
      • 3.3.1. Side Effects Associated with the Hormonal Therapy
    • 3.4. Market Trends
      • 3.4.1. Rising Clinical Trial and Product Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pediatric Growth Hormones, by Route of Administration, Indication, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pediatric Growth Hormones (Value)
      • 5.2.1. Global Pediatric Growth Hormones by: Route of Administration (Value)
        • 5.2.1.1. Intravenous
        • 5.2.1.2. Intramuscular
        • 5.2.1.3. Subcutaneous
        • 5.2.1.4. Oral
      • 5.2.2. Global Pediatric Growth Hormones by: Indication (Value)
        • 5.2.2.1. Growth Hormone Deficiency
        • 5.2.2.2. Turner Syndrome
        • 5.2.2.3. Renal Insufficiency
        • 5.2.2.4. Short Stature
        • 5.2.2.5. Prader-Willi Syndrome
        • 5.2.2.6. Noonan Syndrome
        • 5.2.2.7. Others
      • 5.2.3. Global Pediatric Growth Hormones by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Drug Stores
        • 5.2.3.4. Online Pharmacies
      • 5.2.4. Global Pediatric Growth Hormones Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Pediatric Growth Hormones: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck KGaA (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novo Nordisk A/S (Denmark)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Ferring B.V (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Genentech, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly & Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. BioPartners GmbH (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Pediatric Growth Hormones Sale, by Route of Administration, Indication, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pediatric Growth Hormones (Value)
      • 7.2.1. Global Pediatric Growth Hormones by: Route of Administration (Value)
        • 7.2.1.1. Intravenous
        • 7.2.1.2. Intramuscular
        • 7.2.1.3. Subcutaneous
        • 7.2.1.4. Oral
      • 7.2.2. Global Pediatric Growth Hormones by: Indication (Value)
        • 7.2.2.1. Growth Hormone Deficiency
        • 7.2.2.2. Turner Syndrome
        • 7.2.2.3. Renal Insufficiency
        • 7.2.2.4. Short Stature
        • 7.2.2.5. Prader-Willi Syndrome
        • 7.2.2.6. Noonan Syndrome
        • 7.2.2.7. Others
      • 7.2.3. Global Pediatric Growth Hormones by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Drug Stores
        • 7.2.3.4. Online Pharmacies
      • 7.2.4. Global Pediatric Growth Hormones Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pediatric Growth Hormones: by Route of Administration(USD Million)
  • Table 2. Pediatric Growth Hormones Intravenous , by Region USD Million (2015-2020)
  • Table 3. Pediatric Growth Hormones Intramuscular , by Region USD Million (2015-2020)
  • Table 4. Pediatric Growth Hormones Subcutaneous , by Region USD Million (2015-2020)
  • Table 5. Pediatric Growth Hormones Oral , by Region USD Million (2015-2020)
  • Table 6. Pediatric Growth Hormones: by Indication(USD Million)
  • Table 7. Pediatric Growth Hormones Growth Hormone Deficiency , by Region USD Million (2015-2020)
  • Table 8. Pediatric Growth Hormones Turner Syndrome , by Region USD Million (2015-2020)
  • Table 9. Pediatric Growth Hormones Renal Insufficiency , by Region USD Million (2015-2020)
  • Table 10. Pediatric Growth Hormones Short Stature , by Region USD Million (2015-2020)
  • Table 11. Pediatric Growth Hormones Prader-Willi Syndrome , by Region USD Million (2015-2020)
  • Table 12. Pediatric Growth Hormones Noonan Syndrome , by Region USD Million (2015-2020)
  • Table 13. Pediatric Growth Hormones Others , by Region USD Million (2015-2020)
  • Table 14. Pediatric Growth Hormones: by Distribution Channel(USD Million)
  • Table 15. Pediatric Growth Hormones Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 16. Pediatric Growth Hormones Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 17. Pediatric Growth Hormones Drug Stores , by Region USD Million (2015-2020)
  • Table 18. Pediatric Growth Hormones Online Pharmacies , by Region USD Million (2015-2020)
  • Table 19. South America Pediatric Growth Hormones, by Country USD Million (2015-2020)
  • Table 20. South America Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 21. South America Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 22. South America Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 23. Brazil Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 24. Brazil Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 25. Brazil Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 26. Argentina Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 27. Argentina Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 28. Argentina Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 29. Rest of South America Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 30. Rest of South America Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 31. Rest of South America Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 32. Asia Pacific Pediatric Growth Hormones, by Country USD Million (2015-2020)
  • Table 33. Asia Pacific Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 34. Asia Pacific Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 35. Asia Pacific Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 36. China Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 37. China Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 38. China Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 39. Japan Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 40. Japan Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 41. Japan Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 42. India Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 43. India Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 44. India Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 45. South Korea Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 46. South Korea Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 47. South Korea Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 48. Taiwan Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 49. Taiwan Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 50. Taiwan Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 51. Australia Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 52. Australia Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 53. Australia Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 56. Rest of Asia-Pacific Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 57. Europe Pediatric Growth Hormones, by Country USD Million (2015-2020)
  • Table 58. Europe Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 59. Europe Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 60. Europe Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 61. Germany Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 62. Germany Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 63. Germany Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 64. France Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 65. France Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 66. France Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 67. Italy Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 68. Italy Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 69. Italy Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 70. United Kingdom Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 71. United Kingdom Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 72. United Kingdom Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 73. Netherlands Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 74. Netherlands Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 75. Netherlands Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 76. Rest of Europe Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 77. Rest of Europe Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 78. Rest of Europe Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 79. MEA Pediatric Growth Hormones, by Country USD Million (2015-2020)
  • Table 80. MEA Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 81. MEA Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 82. MEA Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 83. Middle East Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 84. Middle East Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 85. Middle East Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 86. Africa Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 87. Africa Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 88. Africa Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 89. North America Pediatric Growth Hormones, by Country USD Million (2015-2020)
  • Table 90. North America Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 91. North America Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 92. North America Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 93. United States Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 94. United States Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 95. United States Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 96. Canada Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 97. Canada Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 98. Canada Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 99. Mexico Pediatric Growth Hormones, by Route of Administration USD Million (2015-2020)
  • Table 100. Mexico Pediatric Growth Hormones, by Indication USD Million (2015-2020)
  • Table 101. Mexico Pediatric Growth Hormones, by Distribution Channel USD Million (2015-2020)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Pediatric Growth Hormones: by Route of Administration(USD Million)
  • Table 111. Pediatric Growth Hormones Intravenous , by Region USD Million (2021-2026)
  • Table 112. Pediatric Growth Hormones Intramuscular , by Region USD Million (2021-2026)
  • Table 113. Pediatric Growth Hormones Subcutaneous , by Region USD Million (2021-2026)
  • Table 114. Pediatric Growth Hormones Oral , by Region USD Million (2021-2026)
  • Table 115. Pediatric Growth Hormones: by Indication(USD Million)
  • Table 116. Pediatric Growth Hormones Growth Hormone Deficiency , by Region USD Million (2021-2026)
  • Table 117. Pediatric Growth Hormones Turner Syndrome , by Region USD Million (2021-2026)
  • Table 118. Pediatric Growth Hormones Renal Insufficiency , by Region USD Million (2021-2026)
  • Table 119. Pediatric Growth Hormones Short Stature , by Region USD Million (2021-2026)
  • Table 120. Pediatric Growth Hormones Prader-Willi Syndrome , by Region USD Million (2021-2026)
  • Table 121. Pediatric Growth Hormones Noonan Syndrome , by Region USD Million (2021-2026)
  • Table 122. Pediatric Growth Hormones Others , by Region USD Million (2021-2026)
  • Table 123. Pediatric Growth Hormones: by Distribution Channel(USD Million)
  • Table 124. Pediatric Growth Hormones Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 125. Pediatric Growth Hormones Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 126. Pediatric Growth Hormones Drug Stores , by Region USD Million (2021-2026)
  • Table 127. Pediatric Growth Hormones Online Pharmacies , by Region USD Million (2021-2026)
  • Table 128. South America Pediatric Growth Hormones, by Country USD Million (2021-2026)
  • Table 129. South America Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 130. South America Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 131. South America Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 132. Brazil Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 133. Brazil Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 134. Brazil Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 135. Argentina Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 136. Argentina Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 137. Argentina Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 138. Rest of South America Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 139. Rest of South America Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 140. Rest of South America Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 141. Asia Pacific Pediatric Growth Hormones, by Country USD Million (2021-2026)
  • Table 142. Asia Pacific Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 143. Asia Pacific Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 144. Asia Pacific Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 145. China Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 146. China Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 147. China Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 148. Japan Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 149. Japan Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 150. Japan Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 151. India Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 152. India Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 153. India Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 154. South Korea Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 155. South Korea Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 156. South Korea Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 157. Taiwan Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 158. Taiwan Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 159. Taiwan Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 160. Australia Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 161. Australia Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 162. Australia Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 166. Europe Pediatric Growth Hormones, by Country USD Million (2021-2026)
  • Table 167. Europe Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 168. Europe Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 169. Europe Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 170. Germany Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 171. Germany Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 172. Germany Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 173. France Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 174. France Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 175. France Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 176. Italy Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 177. Italy Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 178. Italy Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 179. United Kingdom Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 180. United Kingdom Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 181. United Kingdom Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 182. Netherlands Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 183. Netherlands Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 184. Netherlands Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 185. Rest of Europe Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 186. Rest of Europe Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 187. Rest of Europe Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 188. MEA Pediatric Growth Hormones, by Country USD Million (2021-2026)
  • Table 189. MEA Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 190. MEA Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 191. MEA Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 192. Middle East Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 193. Middle East Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 194. Middle East Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 195. Africa Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 196. Africa Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 197. Africa Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 198. North America Pediatric Growth Hormones, by Country USD Million (2021-2026)
  • Table 199. North America Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 200. North America Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 201. North America Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 202. United States Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 203. United States Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 204. United States Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 205. Canada Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 206. Canada Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 207. Canada Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 208. Mexico Pediatric Growth Hormones, by Route of Administration USD Million (2021-2026)
  • Table 209. Mexico Pediatric Growth Hormones, by Indication USD Million (2021-2026)
  • Table 210. Mexico Pediatric Growth Hormones, by Distribution Channel USD Million (2021-2026)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pediatric Growth Hormones: by Route of Administration USD Million (2015-2020)
  • Figure 5. Global Pediatric Growth Hormones: by Indication USD Million (2015-2020)
  • Figure 6. Global Pediatric Growth Hormones: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Pediatric Growth Hormones Share (%), by Country
  • Figure 8. Asia Pacific Pediatric Growth Hormones Share (%), by Country
  • Figure 9. Europe Pediatric Growth Hormones Share (%), by Country
  • Figure 10. MEA Pediatric Growth Hormones Share (%), by Country
  • Figure 11. North America Pediatric Growth Hormones Share (%), by Country
  • Figure 12. Global Pediatric Growth Hormones share by Players 2020 (%)
  • Figure 13. Global Pediatric Growth Hormones share by Players (Top 3) 2020(%)
  • Figure 14. Global Pediatric Growth Hormones share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 17. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 18. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 19. Novo Nordisk A/S (Denmark) Revenue: by Geography 2020
  • Figure 20. Ferring B.V (Netherlands) Revenue, Net Income and Gross profit
  • Figure 21. Ferring B.V (Netherlands) Revenue: by Geography 2020
  • Figure 22. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Genentech, Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Eli Lilly & Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. Eli Lilly & Company (United States) Revenue: by Geography 2020
  • Figure 28. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 30. BioPartners GmbH (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. BioPartners GmbH (Switzerland) Revenue: by Geography 2020
  • Figure 32. Global Pediatric Growth Hormones: by Route of Administration USD Million (2021-2026)
  • Figure 33. Global Pediatric Growth Hormones: by Indication USD Million (2021-2026)
  • Figure 34. Global Pediatric Growth Hormones: by Distribution Channel USD Million (2021-2026)
  • Figure 35. South America Pediatric Growth Hormones Share (%), by Country
  • Figure 36. Asia Pacific Pediatric Growth Hormones Share (%), by Country
  • Figure 37. Europe Pediatric Growth Hormones Share (%), by Country
  • Figure 38. MEA Pediatric Growth Hormones Share (%), by Country
  • Figure 39. North America Pediatric Growth Hormones Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck KGaA (Germany)
  • Novo Nordisk A/S (Denmark)
  • Ferring B.V (Netherlands)
  • Genentech, Inc. (United States)
  • Pfizer Inc. (United States)
  • Eli Lilly & Company (United States)
  • Novartis AG (Switzerland)
  • BioPartners GmbH (Switzerland)
Select User Access Type

Key Highlights of Report


Apr 2021 218 Pages 68 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pediatric Growth Hormones Market Quantitative research analysis
Global Pediatric Growth Hormones Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Growing Number of Endocrine Disorders " is seen as one of major growth factors of Pediatric Growth Hormones Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Pediatric Growth Hormones Market Report?

Have a Query? Click Here

Other Related Reports

Bovine Ephemeral Fever Vaccines Comprehensive Study by Application (Cattle, Buffaloes), Vaccine Type (Live Vaccine, Killed Vaccine), End User (Medical Device Companies, Pharmaceutical industries, An...
$ 3650
Dental Resin Composites Comprehensive Study by Type (Bulk fill composite, Universal composite, Flowable composite, Others), Application (Dental fillings, Dental crowns, Dental bridges, Others), Compo...
$ 3750
Ocaliva Comprehensive Study by Application (Primary Biliary Cirrhosis, Non-alcoholic Fatty Liver Disease, Other), Distribution Channel (Online, Offline), End-User (Hospitals, Cancer Centres, Others),...
$ 3350
Lithium Medication Comprehensive Study by Type (Tablets, Capsules, Oral Solution), Application (Hospitals, Clinics, Others), Distribution Channel (Online Pharmacies, Retail Pharmacies, Online, Others...
$ 3500
Dietary Supplements Ingredients Comprehensive Study by Type (Andarine, Higenamine, Octopamine, Sodium Tetrachloroaurate, Cesium Chloride, Others), Application (Additional Supplements, Medicinal Suppl...
$ 3450
Glatiramer Comprehensive Study by Type (Brand Medicine, Generic Drug), Application (Hospital, Pharmacy, Other), Route of Administration (Enteral Route, Parenteral Route), Intake Form (Alone, With Oth...
$ 3500